Mark Cockett, PhD

Mark has over 30 years’ biotech and pharmaceutical industry experience delivering medicines from discovery into clinical development. His teams have delivered dozens of development candidates, that include small molecules and biologics, several of which have made it all the way to become marketed products and continue to impact patient lives.

Most recently serving as an Executive in Residence for Yale Ventures and independent consultant to several biotech companies, he has been working with new companies to help hone their business plan, and obtain financing. He has previous experience leading a small biotech in New Haven, CT (Alphina Therapeutics) as CEO and President, R&D. Prior to this he held multiple leadership positions in pharma including Head of Discovery at ViiV Healthcare, advancing new HIV drug candidates through to launch; Head of Discovery Infectious Diseases at Bristol-Myers Squibb (BMS) where he led a dedicated team in the development of several antiviral therapeutics; Previously at BMS he led their Applied Genomics team, supporting all therapeutic areas with genomic technologies, to discover and validate new targets as well as support the quality of all targets and biomarkers in the pipeline with high quality genomic data and resources. Previously he was a scientist and scientific director at Wyeth Research and Celltech PLC, a UK biotech company.